FDA Approves New Long-Acting Insulin Toujeo Max SoloStar

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

Long-acting insulins are only administered once or twice daily, and include drugs like Lantus, Toujeo, Basaglar, and Levemir. As of March 27th, we have a new one to add to the long-acting insulin family – Toujeo Max SoloStar.

What is Toujeo Max SoloStar indicated for?

Toujeo Max SoloStar is indicated to improve blood sugar control in adults with diabetes. It will be available in a 3 ml disposable prefilled SoloStar pen in the strength of 300 units/ml.

Is there anything I should know about the Toujeo Max SoloStar pen?

Yes. The Toujeo Max SoloStar pen delivers doses in two unit increments and can deliver up to 160 units in a single injection. It is recommended for patients requiring at least 20 units per day.  

Do not re-use pen needles.  A new needle must be attached before each injection. Reuse of needles increases the risk of blocked needles which may cause underdosing or overdosing.

Toujeo Max SoloStar holds 900 units of Toujeo, more insulin than any other long-acting insulin pen in the U.S. The maximum dose of up to 160 Units/mL may also help reduce the number of injections needed to deliver the required Toujeo dosage for some adults with diabetes.

Put drug prices & coupons in your pocket!
We'll text you a link to download our free Android or iPhone app
Get GoodRx Mobile App

What will Toujeo Max SoloStar cost?

According to the press release from the manufacturer, Sanofi, Toujeo Max SoloStar will be available at the same price as the original Toujeo SoloStar per insulin unit. 

Additionally, Sanofi will offer a savings program for Toujeo that includes both the SoloStar pen and Max SoloStar pen.

Eligible commercially insured patients will pay a $0 copay if they are new to Toujeo for their first three prescription fills, and a $10 copay for their next 12 fills.

Toujeo Max SoloStar will launch in retail pharmacies across the U.S. in the 3rd quarter of 2018.

Drugs featured in this story

Filed under